Frequency and clinical impact of CDKN2A/ARF/CDKN2B gene deletions as assessed by in-depth genetic analyses in adult T cell acute lymphoblastic leukemia

Table 1 Association between the CNA status for the CDKN2A/ARF/CDKN2B locus and early response to treatment as assessed by the MRD levels detected at the end of induction therapy

CDN2A/ARF/CDKN2B gene status	MRD ≤ 0.1%	P value	MRD ≤ 0.01%	P value
CDKN2A/ARF
Bi or mono-allelic deletion (n = 30)	27 (90)	0.04	22 (73)	0.03
No deletion (n = 30)	17 (68)	0.04	11 (44)	0.03
CDKN2B
Bi or mono-allelic deletion (n = 27)	24 (89)	0.10	19 (70)	0.12
No deletion (n = 28)	20 (71)	0.10	14 (50)	0.12
CDKN2A/ARF and/or CDKN2B
Bi or mono-allelic deletion (n = 32)	29 (91)	0.02	24 (75)	0.007
No deletion (n = 23)	15 (65)	0.02	9 (39)	0.007

ISSN: 1756-8722